Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

2020 Year in Review - Breast Cancer —January 25, 2021


Breast Cancer

In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.

In the MONARCH 2 study, abemaciclib, an oral selective CDK4/6 inhibitor, plus fulvestrant demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared with placebo plus fulvestrant in hormone receptor–positive, HER2-negative advanced breast cancer. Numerically more pronounced improvement in PFS and OS was noted in subgroups with visceral disease and primary endocrine resistance.

Patrick Neven, MD, PhD, Oncologist, Gynecologic Oncology, University Hospital Leuven, Belgium, and colleagues reported PFS and OS for MONARCH 2 with respect to first- and second-line treatment outcomes.

This was an international, randomized, double-blind phase 3 trial of abemaciclib and fulvestrant (N = 446) or placebo and fulvestrant (N = 223) in women with endocrine therapy–resistant, hormone receptor–positive, HER2-negative advanced breast cancer regardless of menopausal status. Stratification of patients was conducted by resistance to previous endocrine therapy (primary vs secondary) and site of metastasis (visceral, bone-only, or other).

In 2019, at the time of data cutoff, the effect of abemaciclib and fulvestrant compared with placebo and fulvestrant was consistent across first-line therapy and second-line therapy. The subanalysis revealed no statistically significant impact on PFS (P = .341) or OS (P = .265). For patients receiving it as first-line therapy, improvement in PFS was demonstrated (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45-0.73); within this population, there was also a positive impact on OS (HR, 0.85; 95% CI, 0.64-1.14). In the second-line therapy setting, efficacy was similar as shown in data from PFS (HR, 0.48; 95% CI, 0.36-0.64) as well as OS (HR, 0.66; 95% CI, 0.46-0.94).

The most profound effects were shown in the first-line therapy population in which patients had less favorable prognostic indicators, such as primary endocrine therapy resistance (PFS: HR, 0.40; 95% CI, 0.26-0.63; OS: HR, 0.58; 95% CI, 0.35-0.97) and visceral disease (PFS: HR, 0.54; 95% CI, 0.39-0.73; OS: HR, 0.82; 95% CI, 0.57-1.17).

The investigators concluded that, in the MONARCH 2 study, the observed statistically significant benefit was across first- and second-line therapy patients. In patients treated with abemaciclib and fulvestrant in the first-line therapy setting, improvements were observed for PFS and OS with profound effects noted in patients with resistance to primary endocrine therapy and visceral disease.

Source: Neven P, Johnston SRD, Toi M, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer. J Clin Oncol. 2020;38(15_suppl). Abstract 1061.

Related Articles
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
Last modified: March 11, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code